RegCell Raises $44M Series A Led by Playground Global for Treg Therapies

RegCell Closes $44M Series A

RegCell, Inc., an Emeryville, California-based biotechnology company, has raised $44 million in Series A funding. The round was announced on September 15, 2026, and was led by Playground Global.

What RegCell Does

RegCell is developing regulatory T-cell (Treg) therapies aimed at restoring immune tolerance in autoimmune disease and transplantation. The company's epigenetic reprogramming platform builds on the discovery of Tregs by Nobel Laureate co-founder Shimon Sakaguchi.

Tregs play a critical role in regulating the immune system and preventing autoimmune reactions. RegCell's approach seeks to harness these cells to treat conditions where the immune system attacks the body's own tissues or rejects transplanted organs.

Company Background

Founded in Japan, RegCell redomiciled to the United States in 2025. The company is now headquartered in Emeryville, California, placing it within one of the world's leading biotech clusters. Its scientific foundation is rooted in the pioneering work of Shimon Sakaguchi, whose discovery of regulatory T cells earned him a Nobel Prize.

Investor Syndicate

The Series A was led by Playground Global, a venture capital firm focused on deep technology and life sciences. Additional investors include:

• LG Technology Ventures
• UTEC
• Global Brain Corporation
• Osaka University Venture Capital Co., Ltd.
• Alumni Ventures
• Mitsui Chemicals
• Fast Track Initiative
• Kyoto University Innovation Capital
• Medical Incubator Japan

The diverse group of investors spans the United States and Japan, reflecting RegCell's trans-Pacific origins and the global interest in its platform.

Acquisition Relevance

For acquirers in the pharmaceutical and biotechnology sectors, RegCell offers a differentiated approach to immune tolerance with a platform based on Nobel Prize-winning science. The company's focus on autoimmune disease and transplantation addresses large unmet medical needs. Strategic buyers could view RegCell as a potential source of next-generation therapies that modulate the immune system rather than broadly suppressing it.

Outlook

With $44 million in fresh capital, RegCell is positioned to advance its Treg therapies toward clinical development. The strong investor syndicate and the company's deep scientific roots suggest a promising trajectory in the competitive field of cell therapy.